Who are Direct Acting Antivirals's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Daclatasvir + Sofosbuvir, Clinically prescribed direct acting antiviral, Sofosbuvir and Velpatasvir, Daclinza and Sunvepra, Zepatier plus Sofosbuvir, Sofosbuvir / Velpatasvir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/direct-acting-antivirals.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Direct Acting Antivirals — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Direct Acting Antivirals (Direct Acting Antivirals) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct-acting antiviral (DAA). Area: Virology/Infectious Disease.

marketed Direct-acting antiviral (DAA) Virology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Direct Acting Antivirals (Direct Acting Antivirals) — Medical University of Warsaw. Direct-acting antivirals inhibit viral enzymes or proteins required for viral replication, preventing the virus from multiplying within host cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Direct Acting Antivirals TARGET	Direct Acting Antivirals	Medical University of Warsaw	marketed	Direct-acting antiviral (DAA)
Daclatasvir + Sofosbuvir	Daclatasvir + Sofosbuvir	Federal University of São Paulo	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Clinically prescribed direct acting antiviral	Clinically prescribed direct acting antiviral	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA)
Sofosbuvir and Velpatasvir	Sofosbuvir and Velpatasvir	Hannover Medical School	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein
Daclinza and Sunvepra	Daclinza and Sunvepra	Pusan National University Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase
Zepatier plus Sofosbuvir	Zepatier plus Sofosbuvir	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A, NS3/4A protease, NS5B RNA polymerase
Sofosbuvir / Velpatasvir	Sofosbuvir / Velpatasvir	Peking University First Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5B polymerase and NS5A protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct-acting antiviral (DAA) class)

Massachusetts General Hospital · 1 drug in this class
Medical University of Warsaw · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Direct Acting Antivirals — Competitive Intelligence Brief. https://druglandscape.com/ci/direct-acting-antivirals. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab